We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Arecor Therapeutics Plc | AREC | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 132.50 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 132.50 | 132.50 | 132.50 | 132.50 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 28/2/2024 10:43 by supernumerary Thanks - I though that was the case - one of those rare cases when I seem to remember regretting missing out. Usually I'm not a fan of allowing tax to influence investment decisions - it must have been very difficult here after the big spike when one would normally sell at least some in order to lock in the profit.Admission was early June, so I guess in 3 months' time we'll get a more accurate view of how those investors now feel... |
Posted at 27/2/2024 15:18 by supernumerary The board monitor speaks! Let me just point out that gratuitous advice is better aimed at those who might be inclined to take it. Not me, I'm afraid.Sorry I didn't go back to the very beginning in mid-2021, although I was around here then. In fact, it more or less doubled just a few months after listing - some very over-optimistic investors - and has been falling ever since. So that's nearly 2.5 years of steadyish decline. Your 'explanation' is, to say the least, incomplete. In any event, if true, I'm somewhat surprised that Downing have managed to go below the 5% threshold without issuing a TR-1. Which fund or funds are involved? SBP - were shares issued under EIS? If so, when does the tax lock-in expire - 3 years from listing date? |
Posted at 24/2/2023 22:01 by sharesoc ShareSoc is hosting a webinar with Arecor Therapeutics plc (AREC) on 07 March 2023, which may be of interest to current shareholders or potential investors. Sarah Howell Ph.D (Chief Executive Officer) and Susan Lowther (Chief Financial Officer) will be presenting. You can register here: |
Posted at 24/2/2023 17:54 by supernumerary May be of interest to investors here; I don't think it has any short term impact on Arecor either way.Researchers: 'We have miscalculated for decades. Half of an insulin dose may not work as expected' by University of Copenhagen New research suggests that a large portion of a diabetic's insulin dose is unlikely to work as expected. University of Copenhagen researchers have discovered that we have miscalculated insulin behavior for many years. The discovery provides a tool for developing better insulin preparations that are depended upon by millions of people worldwide. If you are one of the many millions of type 1 diabetics worldwide, you know that there is a difference in how rapidly and for how long insulin preparations work in the body. For diabetics, these differences are crucial for effective treatment. Getting too little or too much insulin can lead to blood sugar that is either too low or high. Both conditions can be dangerous. The absorption of insulin in the body is controlled by how insulin molecules assemble themselves in clusters. Whereas a single molecule provides rapid action in the body, clusters of six molecules—know But with the help of highly advanced single molecule microscopy, researchers at the University of Copenhagen, in collaboration with Aarhus University, have become the first to demonstrate that this important point has been wrong for years. "It is now apparent to us that we've gotten things wrong by 200 percent. There are only half as many single molecules in insulin compared to what we thought. Conversely, there are far more six-molecule clusters than we assumed. Ultimately, if this is basic research insights apply in human body, it means that when we believe to be administering a certain dose, it may only be half the dose with the rapid-acting effect in the body that we had expected," says Professor Nikos Hatzakis of the Department of Chemistry, the study's lead author. In other words, much of the insulin that diabetics currently put into their bodies may not actually be getting absorbed as expected. While the researchers emphasize that this is not outright dangerous for patients, it does show that there is great potential for the development of more precise medications. The study, Enhanced Hexamerization of Insulin via Assembly Pathway Rerouting Revealed by Single Particle Studies, has just been published in Communications Biology. [ ... ] |
Posted at 05/5/2022 08:00 by alloa2003 This one is being overlooked but so many investors. While focus is on diabetes, there is much much more to this company. |
Posted at 06/4/2022 08:04 by jimbo123elf I agree i'm glad this stock is largely free from traders. I'd much rather have a shareholder base of serious investors who really understand the company and its pioneering science. Our current significant shareholders BGF, Unilever, Calculus, Downing, Albion, Chelverton, Unicorn and Amati know exactly why they are here. |
Posted at 06/4/2022 07:55 by stupidboypike alloa, thank goodness I think Arecor shares are relatively free from traders. I'm not expecting any surprises (good or bad) on 25th, it's not like their sales (or costs) will have suddenly changed from expectations. Next news we are expecting is progress on the Hikma deal sometime in H1 2022, then news on the AT247 trial which completes H2 2022. In my view this is not a share for traders, but long term serious investors.Best regards SBP |
Posted at 29/3/2022 07:18 by alloa2003 This share seems to be flying under the radar of many investors which is a shame as it seems to have a lot to offer. |
Posted at 02/3/2022 21:24 by sharesoc We are hosting a webinar with Arecor Therapeutics plc (AREC) on 15 March 2022, which may be of interest to current shareholders or potential investors. Sarah Howell (Chief Executive Officer) will be presenting. You can register here: |
Posted at 04/6/2021 21:36 by timbo003 >>>>PharI am not surprised that that ii couldnt help you, I don't think any of the cheap and cheerful online brokers would either, they dont get involved with small AIM listed IPOs and placing. Also Panmure Gordon wouldn't be able to help as they do not deal with retail investors. In order to participate in this sort of IPO you need to sign up with one or more private client brokers (which is a relatively easy process and costs nothing). I managed to pick up a few (EIS qualifying shares) shares in the IPO through this route, but got scaled back by 66% ☹️ I also bought a few this week in the market for my SIPP, so I now have (for me) a meaningful amount 🙂 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
